The Association Between Psoriasis and Intestinal Bacterial Population (PIB)

Assuta Hospital Systems

Status: Completed

Conditions: Psoriasis

Study type: Observational

Funder types: Other

Identifiers

NCT02417792

2

Details and patient eligibility

About

At least 20 psoriasis patients will be compared to at least 20 participants without psoriasis Bacterial genomic DNA will be extracted from stool samples of participants. The intestinal bacterial populations will be compared in order to examine whether there are differences between the groups.

Full description

Intestinal bacterial population has a significant influence on health and sickness conditions. It affects the development and the function of the immune system (Th2, Th1 or Th17) by bacterial protein expression and by the composition of the bacterial population.

Psoriasis is an immune related dermal disease. The trigger for this disease is currently unknown but, it is possible that intestinal bacteria are a factor in its development.

Study design:

Participants will be divided into 3 groups:

• Psoriasis patients treated with topical medications
• Psoriasis patients treated with IV or sub-cutaneous medications (e.g biological medications)
• Healthy participants (control group) Bacterial genomic DNA will be extracted from stool samples of participants. The intestinal bacterial populations will be compared in order to examine whether there are differences between the groups.

Enrollment: 46 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Dermal psoriasis patients diagnosed by a dermatologist.

Exclusion criteria

• Treatment with antibiotics or probiotics within the prior 3 months.
• incapable of signing an inform concent.

Trial design

46 participants in 3 patient groups

control

Description:

group of healthy participants

Topical psoriasis treatment

Description:

Group of patients who are treated with topical medications for psoriasis

Systemic psoriasis treatment

Description:

Group of patients who are treated with systematic medications for psoriasis